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Abstract: Fatigue has a profound impact on health-related quality of life (HRQOL) and the aim of
this study is to describe the clinical characteristics and HRQOL for head and neck
cancer patients who raise the issue of fatigue on the Patient Concerns Inventory (PCI),
at their review consultation. Eight consultants were randomised to use the PCI as part
of a cluster-controlled trial. Patients also completed the UW-QoLv4 (University of
Washington Quality of Life), EQ-5D-5L (EuroQol Group) and Distress Thermometer.
There were 140 patients who attended clinics at a median (IQR) of 108 (70-165) days
after the end of treatment. The PCI item ‘fatigue’ was the 6th most commonly selected,
by 29% (40). Those with advanced tumours were more likely (36% 30/83 Vs 18%
10/56, p=0.02) to have selected the item, as were those treated with radiotherapy +/-
chemotherapy (39% 34/87 Vs 11% 6/53, p<0.001). The PCI fatigue group reported
significantly worse overall QOL, social-emotional and physical function composite
scores, distress thermometer, and EQ-5D. PCI-fatigue was common in those with
sleeping, nausea, mood, depression, mobility, breathing and energy level concerns. In
conclusion, given the problems associated with fatigue, it is appropriate to screen and
seek interventions that might help patient address this.
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Table 1 : Selection of the PCI ‘fatigue’ item, by casemix   
 
     




  % Patients  
 Total patients 29 40/140  
Hospital Aintree 27 22/82 
0.70 
 Leeds 31 18/58 
Days from diagnosis to first clinic 
(TERTILES) 
≤144 19 9/48 
0.16 125-227 36 16/45 
 ≥228 32 15/47 
Days from end of treatment to first 
clinic (TERTILES) 
≤79 29 14/49 
0.84 80-138 26 12/46 
 ≥139 31 14/45 
Duration of consultation (minutes) 
TERTILES 
≤8 mins 11 4/37  
9-12 mins 29 14/49 0.005 
 ≥13 mins 42 21/50  
Gender Female 37 18/49 
0.12 
 Male 24 22/91 
Age  <55 38 11/29  
 55-64 26 16/52 0.48 
 65-74 31 10/32  
 ≥75 18 3/17  
Tumour site: Oral cavity 18 10/55 
0.10 
 Oropharynx 36 15/42 
 Larynx 30 9/30 
 Other 46 6/13 
Overall clinical stage Advanced 3-4 36 30/84 
0.02 
 Early 1-2 18 10/56 
Primary treatment*: S only 13 6/46 
0.004 
 S only & FF - 0/7 
RT or RT/CT only 39 15/38 
S & (RT or RT/CT) 45 14/31 
S & (RT or RT/CT) & FF 28 5/18 
WHO comorbidity  0 32 28/88 
0.55  1 25 7/28 
 2-4 21 5/24 
ACE27 comorbidity None 32 23/71 
0.25 
 Mild 24 10/41 
 Moderate 20 5/25 
 Severe 67 2/3 
Living situation Alone in house/flat 17  5/29 
0.17 
 With others in house/flat 32 35/111 
Working Yes 29 14/48 
>0.99 
 No 29 25/86 
Financial benefits Yes 31 15/49 
0.69 
 No 27 21/78 
Smoking habit Current 19 3/16 
0.48  Former 27 22/81 
 Never 34 13/38 
Alcohol habit Current 24 24/100 
0.10  Former 37 11/30 
 Never 60 3/5 
IMD 2019 quintile 1=least deprived 50 8/16 
0.32 
 2 28 8/29 
 3 18 4/22 
 4 24 4/17 
 5=most deprived 29 16/56 
* Surgery (S), RadioTherapy (RT), ChemoTherapy (CT), Free Flap transfer (FF) 







Table 2: Selection of the PCI ‘fatigue’ item, by QOL measures  
     




  % Patients  
 All patients 29 40/140  
UWQOL Overall Quality of 
life 
Outstanding/ Very good 11 5/47 
0.002 
Good 31 15/48 
 Fair 41 14/34 
 Very Poor / Poor  55 6/11 
Distress thermometer (DT) Zero 11 4/36 
0.02 
 1-3 26 10/38 
 4-5 39 13/33 
 6-10 39 13/33 
UWQOL social-emotional 
subscale 
<60 52 13/25  
60-79 40 21/53 <0.001 
80-100 10 6/62  
UWQOL physical function 
subscale 
<60 39 16/41  
60-79 36 20/55 0.001 
 80-100 9 4/44  






Social-emotional subscale     
 Pain Best possible response  17 9/53 
0.05  Somewhere in-between 33 16/48 
 Dysfunction 38 15/39 
 Activity Best possible response  7 3/46 
<0.001  Somewhere in-between 36 29/80 
 Dysfunction 57 8/14 
 Recreation Best possible response  11 7/61 
<0.001  Somewhere in-between 39 28/71 
 Dysfunction 63 5/8 
 Shoulder Best possible response  26 22/85 
0.64  Somewhere in-between 34 14/41 
 Dysfunction 29 4/14 
 Mood Best possible response  8 4/48 
<0.001  Somewhere in-between 41 31/75 
 Dysfunction 29 5/17 
 Anxiety Best possible response  15 7/47 
0.003  Somewhere in-between 29 20/69 
 Dysfunction 54 13/24 
Physical function subscale     
 Appearance Best possible response  21 9/43 
0.41  Somewhere in-between 31 27/86 
 Dysfunction 36 4/11 
 Swallowing Best possible response  14 7/50 
0.01  Somewhere in-between 36 26/73 
 Dysfunction 41 7/17 
 Chewing Best possible response  19 11/57 
0.11  Somewhere in-between 36 23/64 
 Dysfunction 32 6/19 
 Speech Best possible response  28 18/64 
0.68  Somewhere in-between 27 18/66 
 Dysfunction 40 4/10 
 Taste Best possible response  12 5/41 
0.008  Somewhere in-between 32 23/72 
 Dysfunction 44 12/27 
 Saliva Best possible response  12 5/41 
0.001  Somewhere in-between 23 11/47 
 Dysfunction 46 24/52 
Other items:     
 Intimacy Best possible response  25 27/110 
0.04  Somewhere in-between 50 12/24 
 Dysfunction 17 1/6 
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 Fear of 
recurrence* 
0 or 25 50 8/16 
0.01 
50 40 17/43 
 75 21 13/62 
 100 11 2/19 
EQ-5D     
Mobility (walking about) No problems 25 24/96 
0.36  Slight problems 37 7/19 
 Moderate/severe/unable 36 9/25 
Self-care (washing or 
dressing myself) 
No problems 24 27/113 
0.03 Slight problems 55 6/11 
 Moderate/severe/unable 44 7/16 
Usual activities No problems 16 12/76 
<0.001  Slight problems 31 11/35 
 Moderate/severe/unable 59 17/29 
Pain (or discomfort) No pain or discomfort 15 8/54 
0.01  Slight pain or discomfort 33 14/42 
 Moderate/severe/extreme 41 18/44 
Anxiety/depression Not anxious or depressed 21 14/67 
0.01  Slightly anxious or depressed 29 17/58 
 Moderate/severe/extreme 60 9/15 
EQ-5D-5L TTO crosswalk 
values (TERTILES) 
≤.6950 45 17/38  
.6951-.8370 31 19/61 0.001 
 ≥.8371 10 4/41  
EQ5D Visual analogue scale 
(VAS) TERTILES 
≤69 46 21/46  
70-81 32 14/44 <0.001 
 ≥82 10 5/50  
 
*(0) I am fearful all the time that my cancer might return and I struggle with this n=2,  (25) I get a lot of fears of recurrence and these can 
really preoccupy my thoughts  n=14,  (50) I am sometimes having fearful thoughts but I can usually manage these (75) I have a little fear 
with occasional thoughts but they don’t really bother me (100) I have no fear of recurrence 
** Fishers Exact test   
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Table 3:  Selection of the PCI ‘fatigue’ item and other PCI data  




  % Patients  
 Patients 29 40/140  
No of PCI selected: overall <5 2 1/57  
 5-9 30 15/50 <0.001 
 10-14 65 13/20  
 ≥15 85 11/13  
PCI items selected by domain:    
Physical function <5 8 6/75  
 5-9 37 16/43 <0.001 
 ≥10 82 18/22  
Cancer treatment   None 24 24/98 
0.11 
 ≥1 38 16/42 
Social care & social 
wellbeing 
None 23 25/109 
0.01 
≥1 48 15/31 
Psychological, emotional 
wellbeing/spiritual 
None 11 7/65  
1 27 12/44 <0.001 
 ≥2 68 21/31  
No. of Health 
professionals selected  
None 23 17/75 
0.05 
≥1 35 23/65 
Other PCI items selected 
by at least 20% of patients 
overall 
Dry mouth 40 27/68 0.005 
Fear of cancer coming back 48 23/48 <0.001 
Dental health/Teeth 44 21/48 0.006 
 Chewing/eating 43 20/46 0.009 
 Salivation 48 22/46 0.001 
 Swallowing 51 20/39 <0.001 
 Taste 42 16/38 0.04 
 Sore mouth  45 15/33 0.03 
 Mucus 48 16/33 0.007 
 Shoulder 45 14/31 0.03 
 Pain in the head and neck 57 17/30 <0.001 
 Cancer treatment 39 11/28 0.17 
Other PCI items* Activity 50 3/6 0.35 
 Appetite 52 14/27 0.004 
 Bowel habit 50 6/12 0.10 
 Breathing 67 6/9 0.02 
 Energy levels 60 15/25 <0.001 
 Indigestion 50 3/6 0.35 
 Mobility 70 7/10 0.006 
 Nausea 83 5/6 0.007 
 Pain elsewhere 54 7/13 0.05 
 Sleeping 81 13/16 <0.001 
 Vomiting 80 4/5 0.02 
 Financial benefits 67 4/6 0.06 
 Speech/voice/being 
understood 
60 9/15 0.01 
 Anxiety 56 9/16 0.02 
 Depression 75 6/8 0.007 
 Memory 60 6/10 0.03 
 Mood 83 5/6 0.007 
 Self-esteem 67 4/6 0.06 
 Personality & temperament 60 3/5 0.14 
Other Health professionals*    
 Oral rehab team 57 4/7 0.10 
 Physiotherapy 63 5/8 0.04 
 Audiologist 50 4/8 0.23 
 
*when these items were selected then Fatigue was selected in at least 50% of the patients. Denominators under 5 were omitted 
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these patients had hypthyroidism and was there a significant correlation with 
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This is a good point but unfortunately, we don’t routinely measure for hypothyroidism in our 
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hypothyroidism. Based on the PCI response and other patient reported outcomes measures 
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blood count and thyroxine function test. 
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Fatigue has a profound impact on health-related quality of life (HRQOL) and the aim of this 
study is to describe the clinical characteristics and HRQOL for head and neck cancer patients 
who raise the issue of fatigue on the Patient Concerns Inventory (PCI), at their review 
consultation. Eight consultants were randomised to use the PCI as part of a cluster-controlled 
trial. Patients also completed the UW-QoLv4 (University of Washington Quality of Life), 
EQ-5D-5L (EuroQol Group) and Distress Thermometer. There were 140 patients who 
attended clinics at a median (IQR) of 108 (70-165) days after the end of treatment. The PCI 
item ‘fatigue’ was the 6th most commonly selected, by 29% (40). Those with advanced 
tumours were more likely (36% 30/83 Vs 18% 10/56, p=0.02) to have selected the item, as 
were those treated with radiotherapy +/- chemotherapy (39% 34/87 Vs 11% 6/53, p<0.001). 
The PCI fatigue group reported significantly worse overall QOL, social-emotional and 
physical function composite scores, distress thermometer, and EQ-5D. PCI-fatigue was 
common in those with sleeping, nausea, mood, depression, mobility, breathing and energy 
level concerns. In conclusion, given the problems associated with fatigue, it is appropriate to 






Head and neck cancer (HNC) survivors commonly experience cancer-related fatigue (CRF) 
and this relates to disease, treatment and individual patient characteristics1. Moderate and 
severe fatigue was reported in one fifth of HNC survivors2. Cancer-related fatigue 
compromises survival rates and negatively impacts on activities of daily living (ADLs) 3. 
Fatigue is a barrier to getting back to work 4. Although the precise mechanism for CRF 
experienced by HNC survivors is unclear and is probably multi-factorial, radiation to the 
central nervous system has been implicated, particularly the treatment dose to the brainstem 
and medulla5.  Neuroinflammation can also contribute to chronic systemic symptoms such as 
fatigue, sleep disturbance, chronic widespread pain, mood disorders, neuropsychiatric 
symptoms, and temperature dysregulation6. Patients receiving intensity-modulated radiation 
therapy (IMRT) seem to have high rates of fatigue, and further research on how inflammation 
contributes to fatigue is needed7. Depression and fatigue symptoms are interlinked and 
correlate to poor health-related quality of life outcomes (HRQOL) 8. Evaluation throughout 
the treatment is important9 and fatigue is at its worse around the 6th week of radiation 
treatment, and slowly improves thereafter10. Various clinical characteristics associated with 
worse fatigue have been suggested for example, younger age, previous radiation, depression, 
and other symptoms such as poor sleep, reduced social activity and cognitive dysfunction 11, 
12. In a study which utilised the Modified Brief Fatigue Inventory (MBFI), comorbidity and 
cancer stage were also implicated13.  It has been suggested that both fatigue and depression 
should be periodically assessed as both are late effects14.  It is already appreciated that fatigue 
is an issue that patients wish to talk about in their consultations but little is known about the 
patient characteristic. Previous reports using the Patient Concerns Inventory (PCI) following 
HNC treatment has placed fatigue as the 5th most frequent item of the 56 items, being 
common in early and late stage disease across all sites (oral, oropharyngeal, laryngeal and 
other) 15.  
 
The aim of this study is to describe the clinical characteristics and HRQOL for those HNC 
patients who raise the issue of fatigue as something they wish to discuss in their review 
consultation. Understanding the complexity of CRF as it relates to clinical characteristics and 
using this knowledge to guide the development of targeted, individualised interventions is 




The methods have been described previously16.  Briefly, the data is from a pragmatic cluster-
controlled trial conducted at two UK Cancer Centres, namely Aintree and Leeds.  Fifteen 
consultants (the clustering factor) were randomised, eight to ‘using’ and seven to ‘not using’ 
an intervention incorporating the PCI prompt list at all their trial clinics. Eligible patients 
were treated curatively for primary or secondary HNC, and included all sites, stages of 
disease and treatments. Patients treated palliatively or with recurrence, history of cognitive 
impairment, psychoses or dementia were excluded.  The focus of this paper is to report 
results from the first ‘baseline’ post-treatment consultation of only the PCI intervention group 
patients.  The PCI prompt list consists of 56 clinical items 17 which patients selected from, at 
clinic, before seeing their consultant. The patient generated list guides the outpatient 
consultation and it covers a range of symptoms and potential problems patients may face after 
treatment. The item relating to fatigue is described as “fatigue/tiredness” on the prompt list , 
and which in this paper we will simply refer to as “fatigue”. Patients were also asked to select 
from a list of 18 types of health professional, who they would ‘like to see or be referred to’. 
Previous work [18] grouped PCI items into four domains:  Physical and Functional well-
being (29 items), Treatment-related (4 items), Social care/Social well-being (9 items)’ 
Psychological and Emotional well-being/Spiritual (14 items).  
 
Clinical and demographic data were collected by a baseline questionnaire or by extraction 
from electronic records. HRQOL and PCI data were completed electronically (iPAD). 
HRQOL data included UW-QOLv4 19, Distress thermometer20 and EQ-5D-5L21. The UW-
QOLv4 questionnaire consists of 12 single question domains, with between 3 and 5 response 
options scaled evenly from 0 (worst) to 100 (best) according to response hierarchy (Rogers 
2002). It also contains a question about overall QOL in which patients are asked to consider 
not only physical and mental health, but also many other factors, such as family, friends, 
spirituality or personal leisure activities that were important to their enjoyment of life. 
Subsequent analysis has led to the development of subscale composite scores22 and domain 
algorithms to screen for significant problems/dysfunction23.  
 
The statistical analysis focussed on variables associated with selection of the fatigue item 
from the PCI prompt list. We considered patient and clinical casemix variables and also a 
wide range of HRQOL measures.  Fishers Exact test was used to compare patient groups 
regarding selection of the fatigue item.  Spearman’s correlation coefficient (rs) was used to 
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assess association between the UWQOL activities domain response options and those of the 
EQ5D-5L usual activities domain.  The PCI trial has ethical approval from North West - 
Liverpool Central Research Ethics Committee REC reference: IRAS 16/NW/0465, Project 
ID: 189554. It also has approval from the Health Research Authority (HRA). The Research 
and Development Department at Aintree University Hospital NHS Trust (AUH) is 
coordinating the trial and AUH is the sponsor for the trial. 
 
Results 
Patients recruited to the trial and having baseline data were first discussed at 
multidisciplinary team (MDT) meetings between January 2017 and December 2018, with 
first trial clinics between April 2017 and October 2019. Of 288 patients in the trial, 140 were 
in the PCI intervention group. Clinics were a median (IQR) of 189 (120-255) days after 
diagnosis and 108 (70-165) after the end of treatment. Characteristics of the 140 PCI group 
patients can be determined from Table 1. 
 
The mean number of items selected by the 140 PCI patients for discussion in their 
consultation was 6.60, median (IQR) 5 (2-9), range 0 to 28 with 15 or more items selected by 
9% (13). The PCI item ‘fatigue’ was the 6th most commonly selected, by 29% (40), coming 
after ‘dry mouth’ (49%, 68), ‘fear of cancer coming back’ (34%, 48), ‘dental health/teeth’ 
(34%, 48), ‘chewing/eating’ (33%, 46) and ‘salivation’ (33%’ 46).  The longer the 
consultation the more likely the fatigue item had been selected for discussion (Table 1). 
Those with advanced tumours were more likely (36% 30/83 Vs 18% 10/56, p=0.02) to have 
selected the fatigue item, as were those having received radiotherapy +/- chemotherapy (39% 
34/87 Vs 11% 6/53, p<0.001).  
 
Selection of the ‘fatigue’ item was associated with most of the measured HRQOL variables 
(Table 2).  In particular, there was a clear gradient of selection with overall QOL, ranging 
from 11% selecting fatigue in patients reporting very good or outstanding QOL to 55% if 
reporting very poor or poor overall QOL. Clear gradients were seen also regarding the 
distress thermometer score, the EQ-5D visual analogue scale and EQ-5D TTO crosswalk 
values. Regarding the UWQOL, this was also evident for both the social-emotional and 
physical function composite scores. Strong associations were seen with the UWQOL activity 
domain, the EQ-5D usual activities domain and also with UWQOL recreation, mood, anxiety, 
saliva and taste domains.  
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The UWQOL activities domain has five response options, namely, (1) I am usually in bed or 
chair and don't leave home, (2) I don't go out because I don't have the strength, (3) I am often 
tired and have slowed down my activities although I still get out (4) There are times when I 
can't keep up my old pace, but not often and (5) I am as active as I have ever been.  Seven 
patients responded to option 1 or option 2 and 86% (6/7) of these selected fatigue for 
discussion in their consultation, as did 52% (27/52) for option 3, 11% (4/35) for option 4 and 
7% (3/46) for option 5. The EQ5D usual activities domain also has five response options (1) I 
have no problems doing my usual activities, (2) I have slight problems doing my usual 
activities, (3) I have moderate problems doing my usual activities, (4) I have severe problems 
doing my usual activities and (5) I am unable to do my usual activities. Six patients selected 
option 4 or option 5 and 83% (5/6) selected fatigue, as did 52% (12/23) for option 3, 31% 
(11/35) for option 2 and 16% (12/76) for option 1.  Spearman correlation between the two 5-
point measures was Rs=-0.55, p<0.001.  
 
Quite clearly the greater the number of PCI items selected the more likely was this number to 
include fatigue (Table 3), and the same could be said for each of the four PCI domains, and 
also if health professionals were also selected.  Only 2 of the 56 PCI items were not selected 
by these patients and 4 had very small denominators of under 5 patients; for 48 of the other 
50 items the selection of fatigue was higher when that item was selected than when that item 
was not selected. When sleeping was selected fatigue was also selected in 81% (13/16); 
higher fatigue selection rates of around 50% and higher were also seen for many variables 
(Table 3) including nausea (83%, 5/6), mood (83%, 5/6), depression (75%, 6/8), mobility 
(70%, 7/10), breathing (67%, 6/9) and energy levels (60%, 15/25).   
 
Discussion 
CRF following the diagnosis of HNC tends to be under-reported, potentially persistent and of 
substantial significance to patients, impacting on HRQOL and survival. There are many 
different aspects including physical, pain, psychological and social factors which contribute to 
patients’ perceived levels of CRF2. The PCI is a well reported prompt list15,16,18 and as well as 
allowing a wide range of factors to be considered it is also an holistic approach to delivering 
patient-centred care. It can be integrated into routine clinics24,25. The specific issue of fatigue 
reported by the PCI has not previously been assessed in detail, and this novel data has been 
taken from a cluster randomisation trial involving eight different consultants. The variety of 
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consultants across two centres, set within the context of routine follow-up consultations means 
that the findings of this study are pertinent to current practice. The sample comprises of the 
range of HNC sites managed by head and neck oncology surgeons. The focus of the assessment 
is around three to six months following completion of treatment. Nautiyal et al1 reported a 
dramatic improvement in fatigue levels across the first 3 months post-treatment, followed by a 
slow improvement over the remainder of the first year, but with higher fatigue levels than those 
of healthy individuals. Although a fatigue specific questionnaire such as the Modified Brief 
Fatigue Inventory (MBFI) was not used, the degree of fatigue experienced by the patient will 
be reflected by the activity and recreation domains of the UW-QOL26,27. There are other factors 
that might contribute to fatigue such as HPV status as this and inflammation were found to be 
independent predictors of fatigue over time28. As the PCI can be used at consultations, the 
prompt of fatigue affords an opportunity for further exploration, plus provision of informal 
advice and support for both patients and their caregivers. Other unmet needs self-report 
measures29 or Vanderbilt Head and Neck Symptom survey30 might fulfil a similar purpose. 
 
Over a quarter of the patients wished to talk about fatigue at their consultations. Fatigue was 
more common when primary treatment related to radiotherapy +/- chemotherapy rather than 
surgery alone, and expressed by patients with advanced stage. In this sample there was little 
obvious difference in the frequency that patients wished to talk about fatigue by age, gender, 
comorbidity and socio-economic group. Those selecting fatigue reported significantly worse 
QOL, lower scores in the UW-QOL domains apart from appearance, chewing, shoulder and 
speech.  In addition, patients reported worse intimacy, fear of recurrence, distress, and were 
more likely to report moderate to extreme problems in usual activities (EQ-5D). Fatigue on 
the PCI was combined with other issues such as appetite, energy levels, sleeping, depression 
and mood and this reflects the complex nature of inter-related symptoms. 
 
In those patients with CRF, anaemia or hypothyroidism, if present should be corrected and 
pain control attended to. In our HNC follow-up strategy there is no protocol for routinely 
checking for anaemia or hypothyroidism. Based on the PCI response and other patient 
reported outcomes measures that ask about activity, recreation or fatigue, it would be possible 
to build in an alert such that low scores in these domains triggers the suggestion to the 
clinician to check the full blood count and thyroxine function test.  
It is possible to consider additional interventions. Even though patients might feel too tired to 
exercise and the symptom persists, there is evidence that if appropriately graded they can 
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complete an exercise programme, with notable benefits. HNC patients can find it a challenge 
to exercise27 and prescription should be individually tailored to patient characteristics 31. A 
clinic-supported, 12-week progressive strength-training exercise intervention for HNC 
patients was associated with significant improvements in physical functioning outcomes and 
improved management of tiredness and fatigue 32. Physical exercise interventions 
demonstrated improvements in physical function, muscular endurance, range of motion, 
overall quality of life, and showed reductions in pain, and fatigue 33. Progressive resistance 
training in cachectic HNC patients during radiotherapy seems to be safe and feasible and may 
have beneficial effects of general fatigue and quality of life34.  A home-based personalized 
behavioural physical activity intervention with fitness graded motion exergames (PAfitME) 
has been shown to be feasible and acceptable with improvement in CRF, ADL dependence, 
cardiorespiratory fitness, balance, muscle strength, and shoulder forward flexion3. Another 
aspect that might make a positive impact is optimisation of nutrition. HNC patients can be 
malnourished at the time of diagnosis and the side-effects of treatment can exacerbate this 
through detrimental effects on loss of taste, mucositis, xerostomia, anorexia, nausea and 
vomiting. Nutritional advice and use of supplements should be used to increase dietary intake 
and to prevent therapy-associated weight loss35. In nasopharyngeal carcinoma patients, 
nutrition counselling combined with head and neck rehabilitation exercises greatly reduced 
fatigue three months after intensity-modulated radiotherapy (IMRT)36.  Poor sleep quality is 
another factor that is related to fatigue and if obstructive sleep apnoea is a contributing factor 
to sleep disturbance this needs to be addressed37. Interventions aimed at the interaction 
between the emotional aspects of fatigue and HNC outcomes are appropriate and can have 
long-term beneficial effects38. In a study of fatigability, depression, and self-esteem among 
HNC patients, Joseph et al reported that over two thirds of patients had fatigue and a larger 
proportion suffered from depression14.  The role of social support is vital as it improves 
emotional adaptation and reduces depressive symptoms. Also, an appreciation of the 
difficulties involved in social activities exacerbated by a sense of fatigue can result in further 
social isolation8. As the issue of CRF tends to be multi-factorial further research is needed 
using complex intervention methodology. 
 
In conclusion, a significant proportion of HNC patients following treatment wish to discuss 
the issue of fatigue during their out-patient consultation. Fatigue is associated with poor 
outcomes. As fatigue can be a patient concern over an extended period of time, the PCI 
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prompt list approach could facilitate the discussion during follow-up and allow for further 
investigation and targeted onward referral based on the aetiology of the fatigue.   
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Table 1 : Selection of the PCI ‘fatigue’ item, by casemix   
 
     




  % Patients  
 Total patients 29 40/140  
Hospital Aintree 27 22/82 
0.70 
 Leeds 31 18/58 
Days from diagnosis to first clinic 
(TERTILES) 
≤144 19 9/48 
0.16 125-227 36 16/45 
 ≥228 32 15/47 
Days from end of treatment to first 
clinic (TERTILES) 
≤79 29 14/49 
0.84 80-138 26 12/46 
 ≥139 31 14/45 
Duration of consultation (minutes) 
TERTILES 
≤8 mins 11 4/37  
9-12 mins 29 14/49 0.005 
 ≥13 mins 42 21/50  
Gender Female 37 18/49 
0.12 
 Male 24 22/91 
Age  <55 38 11/29  
 55-64 26 16/52 0.48 
 65-74 31 10/32  
 ≥75 18 3/17  
Tumour site: Oral cavity 18 10/55 
0.10 
 Oropharynx 36 15/42 
 Larynx 30 9/30 
 Other 46 6/13 
Overall clinical stage Advanced 3-4 36 30/84 
0.02 
 Early 1-2 18 10/56 
Primary treatment*: S only 13 6/46 
0.004 
 S only & FF - 0/7 
RT or RT/CT only 39 15/38 
S & (RT or RT/CT) 45 14/31 
S & (RT or RT/CT) & FF 28 5/18 
WHO comorbidity  0 32 28/88 
0.55  1 25 7/28 
 2-4 21 5/24 
ACE27 comorbidity None 32 23/71 
0.25 
 Mild 24 10/41 
 Moderate 20 5/25 
 Severe 67 2/3 
Living situation Alone in house/flat 17  5/29 
0.17 
 With others in house/flat 32 35/111 
Working Yes 29 14/48 
>0.99 
 No 29 25/86 
Financial benefits Yes 31 15/49 
0.69 
 No 27 21/78 
Smoking habit Current 19 3/16 
0.48  Former 27 22/81 
 Never 34 13/38 
Alcohol habit Current 24 24/100 
0.10  Former 37 11/30 
 Never 60 3/5 
IMD 2019 quintile 1=least deprived 50 8/16 
0.32 
 2 28 8/29 
 3 18 4/22 
 4 24 4/17 
 5=most deprived 29 16/56 
* Surgery (S), RadioTherapy (RT), ChemoTherapy (CT), Free Flap transfer (FF) 






Table 2: Selection of the PCI ‘fatigue’ item, by QOL measures  
     




  % Patients  
 All patients 29 40/140  
UWQOL Overall Quality of 
life 
Outstanding/ Very good 11 5/47 
0.002 
Good 31 15/48 
 Fair 41 14/34 
 Very Poor / Poor  55 6/11 
Distress thermometer (DT) Zero 11 4/36 
0.02 
 1-3 26 10/38 
 4-5 39 13/33 
 6-10 39 13/33 
UWQOL social-emotional 
subscale 
<60 52 13/25  
60-79 40 21/53 <0.001 
80-100 10 6/62  
UWQOL physical function 
subscale 
<60 39 16/41  
60-79 36 20/55 0.001 
 80-100 9 4/44  






Social-emotional subscale     
 Pain Best possible response  17 9/53 
0.05  Somewhere in-between 33 16/48 
 Dysfunction 38 15/39 
 Activity Best possible response  7 3/46 
<0.001  Somewhere in-between 36 29/80 
 Dysfunction 57 8/14 
 Recreation Best possible response  11 7/61 
<0.001  Somewhere in-between 39 28/71 
 Dysfunction 63 5/8 
 Shoulder Best possible response  26 22/85 
0.64  Somewhere in-between 34 14/41 
 Dysfunction 29 4/14 
 Mood Best possible response  8 4/48 
<0.001  Somewhere in-between 41 31/75 
 Dysfunction 29 5/17 
 Anxiety Best possible response  15 7/47 
0.003  Somewhere in-between 29 20/69 
 Dysfunction 54 13/24 
Physical function subscale     
 Appearance Best possible response  21 9/43 
0.41  Somewhere in-between 31 27/86 
 Dysfunction 36 4/11 
 Swallowing Best possible response  14 7/50 
0.01  Somewhere in-between 36 26/73 
 Dysfunction 41 7/17 
 Chewing Best possible response  19 11/57 
0.11  Somewhere in-between 36 23/64 
 Dysfunction 32 6/19 
 Speech Best possible response  28 18/64 
0.68  Somewhere in-between 27 18/66 
 Dysfunction 40 4/10 
 Taste Best possible response  12 5/41 
0.008  Somewhere in-between 32 23/72 
 Dysfunction 44 12/27 
 Saliva Best possible response  12 5/41 
0.001  Somewhere in-between 23 11/47 
 Dysfunction 46 24/52 
Other items:     
 Intimacy Best possible response  25 27/110 
0.04  Somewhere in-between 50 12/24 
 Dysfunction 17 1/6 
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 Fear of 
recurrence* 
0 or 25 50 8/16 
0.01 
50 40 17/43 
 75 21 13/62 
 100 11 2/19 
EQ-5D     
Mobility (walking about) No problems 25 24/96 
0.36  Slight problems 37 7/19 
 Moderate/severe/unable 36 9/25 
Self-care (washing or 
dressing myself) 
No problems 24 27/113 
0.03 Slight problems 55 6/11 
 Moderate/severe/unable 44 7/16 
Usual activities No problems 16 12/76 
<0.001  Slight problems 31 11/35 
 Moderate/severe/unable 59 17/29 
Pain (or discomfort) No pain or discomfort 15 8/54 
0.01  Slight pain or discomfort 33 14/42 
 Moderate/severe/extreme 41 18/44 
Anxiety/depression Not anxious or depressed 21 14/67 
0.01  Slightly anxious or depressed 29 17/58 
 Moderate/severe/extreme 60 9/15 
EQ-5D-5L TTO crosswalk 
values (TERTILES) 
≤.6950 45 17/38  
.6951-.8370 31 19/61 0.001 
 ≥.8371 10 4/41  
EQ5D Visual analogue scale 
(VAS) TERTILES 
≤69 46 21/46  
70-81 32 14/44 <0.001 
 ≥82 10 5/50  
 
*(0) I am fearful all the time that my cancer might return and I struggle with this n=2,  (25) I get a lot of fears of recurrence and these can 
really preoccupy my thoughts  n=14,  (50) I am sometimes having fearful thoughts but I can usually manage these (75) I have a little fear 
with occasional thoughts but they don’t really bother me (100) I have no fear of recurrence 
** Fishers Exact test   
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Table 3:  Selection of the PCI ‘fatigue’ item and other PCI data  




  % Patients  
 Patients 29 40/140  
No of PCI selected: overall <5 2 1/57  
 5-9 30 15/50 <0.001 
 10-14 65 13/20  
 ≥15 85 11/13  
PCI items selected by domain:    
Physical function <5 8 6/75  
 5-9 37 16/43 <0.001 
 ≥10 82 18/22  
Cancer treatment   None 24 24/98 
0.11 
 ≥1 38 16/42 
Social care & social 
wellbeing 
None 23 25/109 
0.01 
≥1 48 15/31 
Psychological, emotional 
wellbeing/spiritual 
None 11 7/65  
1 27 12/44 <0.001 
 ≥2 68 21/31  
No. of Health 
professionals selected  
None 23 17/75 
0.05 
≥1 35 23/65 
Other PCI items selected 
by at least 20% of patients 
overall 
Dry mouth 40 27/68 0.005 
Fear of cancer coming back 48 23/48 <0.001 
Dental health/Teeth 44 21/48 0.006 
 Chewing/eating 43 20/46 0.009 
 Salivation 48 22/46 0.001 
 Swallowing 51 20/39 <0.001 
 Taste 42 16/38 0.04 
 Sore mouth  45 15/33 0.03 
 Mucus 48 16/33 0.007 
 Shoulder 45 14/31 0.03 
 Pain in the head and neck 57 17/30 <0.001 
 Cancer treatment 39 11/28 0.17 
Other PCI items* Activity 50 3/6 0.35 
 Appetite 52 14/27 0.004 
 Bowel habit 50 6/12 0.10 
 Breathing 67 6/9 0.02 
 Energy levels 60 15/25 <0.001 
 Indigestion 50 3/6 0.35 
 Mobility 70 7/10 0.006 
 Nausea 83 5/6 0.007 
 Pain elsewhere 54 7/13 0.05 
 Sleeping 81 13/16 <0.001 
 Vomiting 80 4/5 0.02 
 Financial benefits 67 4/6 0.06 
 Speech/voice/being 
understood 
60 9/15 0.01 
 Anxiety 56 9/16 0.02 
 Depression 75 6/8 0.007 
 Memory 60 6/10 0.03 
 Mood 83 5/6 0.007 
 Self-esteem 67 4/6 0.06 
 Personality & temperament 60 3/5 0.14 
Other Health professionals*    
 Oral rehab team 57 4/7 0.10 
 Physiotherapy 63 5/8 0.04 
 Audiologist 50 4/8 0.23 
 
*when these items were selected then Fatigue was selected in at least 50% of the patients. Denominators under 5 were omitted 
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Prof Simon Rogers 






Dear Prof Rogers 
 
Study title: Improving quality of life through the routine use of the 
Patient Concerns Inventory for head and neck cancer 
patients (PCI-QOL) 
REC reference: 16/NW/0465 
IRAS project ID: 189554 
 
The Research Ethics Committee reviewed the above application at the meeting held on 06 July 
2016.   Thank you for attending to discuss the application.  
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 
of this favourable opinion letter.  The expectation is that this information will be published for all 
studies that receive an ethical opinion but should you wish to provide a substitute contact point, 
wish to make a request to defer, or require further information, please contact the REC Manager 
Mrs Carol Ebenezer, nrescommittee.northwest-liverpoolcentral@nhs.net. Under very limited 
circumstances (e.g. for student research which has received an unfavourable opinion), it may be 





The members of the Committee present gave a favourable ethical opinion of the above research 
on the basis described in the application form, protocol and supporting documentation, subject 
to the conditions specified below. . 
Please note:  This is the 
favourable opinion of the 
REC only and does not allow 
you to start your study at NHS 
sites in England until you 
receive HRA Approval  
 
Ethics





Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study.   
 
the Committee would like to see the Participant Information Sheet revised to 
  i) include a further paragraph “What if something goes wrong?” and state 
that if something goes wrong the normal NHS compensation procedures would apply 
  ii) under “What are the side effects and risks?” add the words “There are no 
perceived risks to taking part but it might inconvenience you by prolonging your clinic time” 
and omit the current wording “This might prolong your clinic time” 
b. the Committee would like to see the PCI revised to replace NHS number with 
unique identifier 
c. the Committee would like to know for how long the data will be kept 
 
You should notify the REC once all conditions have been met (except for site approvals 
from host organisations) and provide copies of any revised documentation with updated 
version numbers. Revised documents should be submitted to the REC electronically from 
IRAS. The REC will acknowledge receipt and provide a final list of the approved 
documentation for the study, which you can make available to host organisations to 
facilitate their permission for the study. Failure to provide the final versions to the REC 
may cause delay in obtaining permissions. 
 
 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned.   
 
Management permission should be sought from all NHS organisations involved in the study in 
accordance with NHS research governance arrangements. Each NHS organisation must confirm 
through the signing of agreements and/or other documents that it has given permission for the 
research to proceed (except where explicitly specified otherwise).  
 
Guidance on applying for HRA Approval (England)/ NHS permission for research is available in 
the Integrated Research Application System, at www.hra.nhs.uk or at 
http://www.rdforum.nhs.uk.  
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database. This should be before the first participant is recruited but no 
later than 6 weeks after recruitment of the first participant. 
  
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 




To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
  
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from the HRA. Guidance on where to register is provided on the HRA website.  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 




The favourable opinion applies to all NHS sites taking part in the study taking part in the study, 
subject to management permission being obtained from the NHS/HSC R&D office prior to the 
start of the study (see “Conditions of the favourable opinion” below).  
 
Non NHS sites 
 
The Committee has not yet completed any site-specific assessment(s) (SSA) for the non-NHS 
research site(s) taking part in this study.  The favourable opinion does not therefore apply to any 
non-NHS site at present.  I will write to you again as soon as an SSA application(s) has been 
reviewed.  In the meantime no study procedures should be initiated at non-NHS sites.  
 
Summary of discussion at the meeting 
 
The Chair welcomed you to the REC and thanked you for attending to discuss the study.  The 
Committee told you that this was a really good and worthwhile study. 
 
Care and protection of research participants; respect for potential and enrolled 
participants’ welfare and dignity 
The Committee pointed out that there was a discrepancy in the stated time for storage of data at 
the end of the study and asked you for how long it would be kept and how it would be destroyed. 
 
You stated that you would check with the NHIR and advise the Committee. 
 
Informed consent process and the adequacy and completeness of participant information 
The Committee advised that some minor changes to the Participant Information Sheet were 
required (as listed on the decision below) and that these would be included in the decision letter. 
 
Suitability of supporting information 
The Committee asked that the PCI be changed to omit the NHS number and include, instead, 
the unique identifier.   
 
You agreed to this and stated that the NHS number was on the form because it was currently 
used in clinical practice. 
 











The documents reviewed and approved at the meeting were: 
 
Document   Version   Date   
IRAS Application Form [IRAS_Form_26052016]    26 May 2016  
Letter from funder [Funder Letter]      
Letter from sponsor [Sponsor Approval Letter]      
Non-validated questionnaire [Distress Thermometer]  1  26 May 2016  
Non-validated questionnaire [EQ-5D-3L Questionnaire]  1  26 May 2016  
Non-validated questionnaire [Preconsultation Questionnaire]  1  26 May 2016  
Non-validated questionnaire [UW-QOL Questionnaire]  4  26 May 2016  
Non-validated questionnaire [CRSI-PCI-QoL]  1  26 May 2016  
Other [email regarding Independent Review]    08 June 2016  
Participant consent form  1  26 May 2016  
Participant information sheet (PIS) [PIS V1 26.5.16]  1  26 May 2016  
Research protocol or project proposal  1  26 May 2016  
Summary CV for Chief Investigator (CI) [Prof Simon Rogers]      
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 




The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-
assurance/  
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Fatigue has a profound impact on health-related quality of life (HRQOL) and the aim of this 
study is to describe the clinical characteristics and HRQOL for head and neck cancer patients 
who raise the issue of fatigue on the Patient Concerns Inventory (PCI), at their review 
consultation. The data is from a cluster-controlled trial conducted at two UK centres. Eight 
consultants were randomised to use the PCI as part of a cluster-controlled trial. Patients also 
completed the UW-QoLv4 (University of Washington Quality of Life), EQ-5D-5L (EuroQol 
Group) UW-QOLv4and , Distress Thermometer. thermometer and EQ-5D-5L. There were 
140 patients who attended clinics at a median (IQR) of 108 (70-165) days after the end of 
treatment. The PCI item ‘fatigue’ was the 6th most commonly selected, by 29% (40). Those 
with advanced tumours were more likely (36% 30/83 Vs 18% 10/56, p=0.02) to have selected 
the item, as were those treated with radiotherapy +/- chemotherapy (39% 34/87 Vs 11% 6/53, 
p<0.001). The PCI fatigue group reported significantly worse overall QOL, social-emotional 
and physical function composite scores, distress thermometer score, and EQ-5D scores. PCI-
fatigue was common in those with sleeping, nausea, mood, depression, mobility, breathing 
and energy level concerns. In conclusion, given the problems associated with fatigue, it is 






Head and neck cancer (HNC) survivors commonly experience cancer-related fatigue (CRF) 
and this relates to disease, treatment and individual patient characteristics1. Moderate and 
severe fatigue was reported in one fifth of HNC survivors2. Cancer-related fatigue 
compromises survival rates and negatively impacts on activities of daily living (ADLs) 3. 
Fatigue is a barrier to getting back to work 4. Although the precise mechanism for CRF 
experienced by HNC survivors is unclear and is probably multi-factorial, radiation to the 
central nervous system has been implicated, particularly the treatment dose to the brainstem 
and medulla5.  Neuroinflammation can also contribute to chronic systemic symptoms such as 
fatigue, sleep disturbance, chronic widespread pain, mood disorders, neuropsychiatric 
symptoms, and temperature dysregulation6. Patients receiving intensity-modulated radiation 
therapy (IMRT) seem to have high rates of fatigue, and further research on how inflammation 
contributes to fatigue is needed7. Depression and fatigue symptoms are interlinked and 
correlate to poor health-related quality of life outcomes (HRQOL) 8. Evaluation throughout 
the treatment is important9 and fatigue is at its worse around the 6th week of radiation 
treatment, and slowly improves thereafter10. Various clinical characteristics associated with 
worse fatigue have been suggested for example, younger age, previous radiation, depression, 
and other symptoms such as poor sleep, reduced social activity and cognitive dysfunction 11, 
12. In a study which utilised the Modified Brief Fatigue Inventory (MBFI), comorbidity and 
cancer stage were also implicated13.  It has been suggested that both fatigue and depression 
should be periodically assessed as both are late effects14.  It is already appreciated that fatigue 
is an issue that patients wish to talk about in their consultations but little is known about the 
patient characteristic. Previous reports using the Patient Concerns Inventory (PCI) following 
HNC treatment has placed fatigue as the 5th most frequent item of the 56 items, being 
common in early and late stage disease across all sites (oral, oropharyngeal, laryngeal and 
other) 15.  
 
The aim of this study is to describe the clinical characteristics and HRQOL for those HNC 
patients who raise the issue of fatigue as something they wish to discuss in their review 
consultation. Understanding the complexity of CRF as it relates to clinical characteristics and 
using this knowledge to guide the development of targeted, individualised interventions is 




The methods have been described previously16.  Briefly, the data is from a pragmatic cluster-
controlled trial conducted at two UK Cancer Centres, namely Aintree and Leeds.  Fifteen 
consultants (the clustering factor) were randomised, eight to ‘using’ and seven to ‘not using’ 
an intervention incorporating the PCI prompt list at all their trial clinics. Eligible patients 
were treated curatively for primary or secondary HNC, and included all sites, stages of 
disease and treatments. Patients treated palliatively or with recurrence, history of cognitive 
impairment, psychoses or dementia were excluded.  The focus of this paper is to report 
results from the first ‘baseline’ post-treatment consultation of only the PCI intervention group 
patients.  The PCI prompt list consists of 56 clinical items 17 which patients selected from, at 
clinic, before seeing their consultant. The patient generated list guides the outpatient 
consultation and it covers a range of symptoms and potential problems patients may face after 
treatment. The item relating to fatigue is described as “fatigue/tiredness” on the prompt list , 
and which in this paper we will simply refer to as “fatigue”. Patients were also asked to select 
from a list of 18 types of health professional, who they would ‘like to see or be referred to’. 
Previous work [18] grouped PCI items into four domains:  Physical and Functional well-
being (29 items), Treatment-related (4 items), Social care/Social well-being (9 items)’ 
Psychological and Emotional well-being/Spiritual (14 items).  
 
Clinical and demographic data were collected by a baseline questionnaire or by extraction 
from electronic records. HRQOL and PCI data were completed electronically (iPAD). 
HRQOL data included UW-QOLv4 19, Distress thermometer20 and EQ-5D-5L21. The UW-
QOLv4 questionnaire consists of 12 single question domains, with between 3 and 5 response 
options scaled evenly from 0 (worst) to 100 (best) according to response hierarchy (Rogers 
2002). It also contains a question about overall QOL in which patients are asked to consider 
not only physical and mental health, but also many other factors, such as family, friends, 
spirituality or personal leisure activities that were important to their enjoyment of life. 
Subsequent analysis has led to the development of subscale composite scores22 and domain 
algorithms to screen for significant problems/dysfunction23.  
 
The statistical analysis focussed on variables associated with selection of the fatigue item 
from the PCI prompt list. We considered patient and clinical casemix variables and also a 
wide range of HRQOL measures.  Fishers Exact test was used to compare patient groups 
regarding selection of the fatigue item.  Spearman’s correlation coefficient (rs) was used to 
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assess association between the UWQOL activities domain response options and those of the 
EQ5D-5L usual activities domain.  The PCI trial has ethical approval from North West - 
Liverpool Central Research Ethics Committee REC reference: IRAS 16/NW/0465, Project 
ID: 189554. It also has approval from the Health Research Authority (HRA). The Research 
and Development Department at Aintree University Hospital NHS Trust (AUH) is 
coordinating the trial and AUH is the sponsor for the trial. 
 
Results 
Patients recruited to the trial and having baseline data were first discussed at 
multidisciplinary team (MDT) meetings between January 2017 and December 2018, with 
first trial clinics between April 2017 and October 2019. Of 288 patients in the trial, 140 were 
in the PCI intervention group. Clinics were a median (IQR) of 189 (120-255) days after 
diagnosis and 108 (70-165) after the end of treatment. Characteristics of the 140 PCI group 
patients can be determined from Table 1. 
 
The mean number of items selected by the 140 PCI patients for discussion in their 
consultation was 6.60, median (IQR) 5 (2-9), range 0 to 28 with 15 or more items selected by 
9% (13). The PCI item ‘fatigue’ was the 6th most commonly selected, by 29% (40), coming 
after ‘dry mouth’ (49%, 68), ‘fear of cancer coming back’ (34%, 48), ‘dental health/teeth’ 
(34%, 48), ‘chewing/eating’ (33%, 46) and ‘salivation’ (33%’ 46).  The longer the 
consultation the more likely the fatigue item had been selected for discussion (Table 1). 
Those with advanced tumours were more likely (36% 30/83 Vs 18% 10/56, p=0.02) to have 
selected the fatigue item, as were those having received radiotherapy +/- chemotherapy (39% 
34/87 Vs 11% 6/53, p<0.001).  
 
Selection of the ‘fatigue’ item was associated with most of the measured HRQOL variables 
(Table 2).  In particular, there was a clear gradient of selection with overall QOL, ranging 
from 11% selecting fatigue in patients reporting very good or outstanding QOL to 55% if 
reporting very poor or poor overall QOL. Clear gradients were seen also regarding the 
distress thermometer score, the EQ-5D visual analogue scale and EQ-5D TTO crosswalk 
values. Regarding the UWQOL, this was also evident for both the social-emotional and 
physical function composite scores. Strong associations were seen with the UWQOL activity 
domain, the EQ-5D usual activities domain and also with UWQOL recreation, mood, anxiety, 
saliva and taste domains.  
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The UWQOL activities domain has five response options, namely, (1) I am usually in bed or 
chair and don't leave home, (2) I don't go out because I don't have the strength, (3) I am often 
tired and have slowed down my activities although I still get out (4) There are times when I 
can't keep up my old pace, but not often and (5) I am as active as I have ever been.  Seven 
patients responded to option 1 or option 2 and 86% (6/7) of these selected fatigue for 
discussion in their consultation, as did 52% (27/52) for option 3, 11% (4/35) for option 4 and 
7% (3/46) for option 5. The EQ5D usual activities domain also has five response options (1) I 
have no problems doing my usual activities, (2) I have slight problems doing my usual 
activities, (3) I have moderate problems doing my usual activities, (4) I have severe problems 
doing my usual activities and (5) I am unable to do my usual activities. Six patients selected 
option 4 or option 5 and 83% (5/6) selected fatigue, as did 52% (12/23) for option 3, 31% 
(11/35) for option 2 and 16% (12/76) for option 1.  Spearman correlation between the two 5-
point measures was Rs=-0.55, p<0.001.  
 
Quite clearly the greater the number of PCI items selected the more likely was this number to 
include fatigue (Table 3), and the same could be said for each of the four PCI domains, and 
also if health professionals were also selected.  Only 2 of the 56 PCI items were not selected 
by these patients and 4 had very small denominators of under 5 patients; for 48 of the other 
50 items the selection of fatigue was higher when that item was selected than when that item 
was not selected. When sleeping was selected fatigue was also selected in 81% (13/16); 
higher fatigue selection rates of around 50% and higher were also seen for many variables 
(Table 3) including nausea (83%, 5/6), mood (83%, 5/6), depression (75%, 6/8), mobility 
(70%, 7/10), breathing (67%, 6/9) and energy levels (60%, 15/25).   
 
Discussion 
CRF following the diagnosis of HNC tends to be under-reported, potentially persistent and of 
substantial significance to patients, impacting on HRQOL and survival. There are many 
different aspects including physical, pain, psychological and social factors which contribute to 
patients’ perceived levels of CRF2. The PCI is a well reported prompt list15,16,18 and as well as 
allowing a wide range of factors to be considered it is also an holistic approach to delivering 
patient-centred care. It can be integrated into routine clinics24,25. The specific issue of fatigue 
reported by the PCI has not previously been assessed in detail, and this novel data has been 
taken from a cluster randomisation trial involving eight different consultants. The variety of 
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consultants across two centres, set within the context of routine follow-up consultations means 
that the findings of this study are pertinent to current practice. The sample comprises of the 
range of HNC sites managed by head and neck oncology surgeons. The focus of the assessment 
is around three to six months following completion of treatment. Nautiyal et al1 reported a 
dramatic improvement in fatigue levels across the first 3 months post-treatment, followed by a 
slow improvement over the remainder of the first year, but with higher fatigue levels than those 
of healthy individuals. Although a fatigue specific questionnaire such as the Modified Brief 
Fatigue Inventory (MBFI) was not used, the degree of fatigue experienced by the patient will 
be reflected by the activity and recreation domains of the UW-QOL26,27. There are other factors 
that might contribute to fatigue such as HPV status as this and inflammation were found to be 
independent predictors of fatigue over time28. As the PCI can be used at consultations, the 
prompt of fatigue affords an opportunity for further exploration, plus provision of informal 
advice and support for both patients and their caregivers. Other unmet needs self-report 
measures29 or Vanderbilt Head and Neck Symptom survey30 might fulfil a similar purpose. 
 
Over a quarter of the patients wished to talk about fatigue at their consultations. Fatigue was 
more common when primary treatment related to radiotherapy +/- chemotherapy rather than 
surgery alone, and expressed by patients with advanced stage. In this sample there was little 
obvious difference in the frequency that patients wished to talk about fatigue by age, gender, 
comorbidity and socio-economic group. Those selecting fatigue reported significantly worse 
QOL, lower scores in the UW-QOL domains apart from appearance, chewing, shoulder and 
speech.  In addition, patients reported worse intimacy, fear of recurrence, distress, and were 
more likely to report moderate to extreme problems in usual activities (EQ-5D). Fatigue on 
the PCI was combined with other issues such as appetite, energy levels, sleeping, depression 
and mood and this reflects the complex nature of inter-related symptoms. 
 
In those patients with CRF, anaemia or hypothyroidism, if present should be corrected and 
pain control attended to. In our HNC follow-up strategy there is no protocol for routinely 
checking for anaemia or hypothyroidism. Based on the PCI response and other patient 
reported outcomes measures that ask about activity, recreation or fatigue, it would be possible 
to build in an alert such that low scores in these domains triggers the suggestion to the 
clinician to check the full blood count and thyroxine function test.  
It is possible to consider additional interventions. Even though patients might feel too tired to 
exercise and the symptom persists, there is evidence that if appropriately graded they can 
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complete an exercise programme, with notable benefits. HNC patients can find it a challenge 
to exercise27 and prescription should be individually tailored to patient characteristics 31. A 
clinic-supported, 12-week progressive strength-training exercise intervention for HNC 
patients was associated with significant improvements in physical functioning outcomes and 
improved management of tiredness and fatigue 32. Physical exercise interventions 
demonstrated improvements in physical function, muscular endurance, range of motion, 
overall quality of life, and showed reductions in pain, and fatigue 33. Progressive resistance 
training in cachectic HNC patients during radiotherapy seems to be safe and feasible and may 
have beneficial effects of general fatigue and quality of life34.  A home-based personalized 
behavioural physical activity intervention with fitness graded motion exergames (PAfitME) 
has been shown to be feasible and acceptable with improvement in CRF, ADL dependence, 
cardiorespiratory fitness, balance, muscle strength, and shoulder forward flexion3. Another 
aspect that might make a positive impact is optimisation of nutrition. HNC patients can be 
malnourished at the time of diagnosis and the side-effects of treatment can exacerbate this 
through detrimental effects on loss of taste, mucositis, xerostomia, anorexia, nausea and 
vomiting. Nutritional advice and use of supplements should be used to increase dietary intake 
and to prevent therapy-associated weight loss35. In nasopharyngeal carcinoma patients, 
nutrition counselling combined with head and neck rehabilitation exercises greatly reduced 
fatigue three months after intensity-modulated radiotherapy (IMRT)36.  Poor sleep quality is 
another factor that is related to fatigue and if obstructive sleep apnoea is a contributing factor 
to sleep disturbance this needs to be addressed37. Interventions aimed at the interaction 
between the emotional aspects of fatigue and HNC outcomes are appropriate and can have 
long-term beneficial effects38. In a study of fatigability, depression, and self-esteem among 
HNC patients, Joseph et al reported that over two thirds of patients had fatigue and a larger 
proportion suffered from depression14.  The role of social support is vital as it improves 
emotional adaptation and reduces depressive symptoms. Also, an appreciation of the 
difficulties involved in social activities exacerbated by a sense of fatigue can result in further 
social isolation8. As the issue of CRF tends to be multi-factorial further research is needed 
using complex intervention methodology. 
 
In conclusion, a significant proportion of HNC patients following treatment wish to discuss 
the issue of fatigue during their out-patient consultation. Fatigue is associated with poor 
outcomes. As fatigue can be a patient concern over an extended period of time, the PCI 
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prompt list approach could facilitate the discussion during follow-up and allow for further 
investigation and targeted onward referral based on the aetiology of the fatigue.   
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Table 1 : Selection of the PCI ‘fatigue’ item, by casemix   
 
     




  % Patients  
 Total patients 29 40/140  
Hospital Aintree 27 22/82 
0.70 
 Leeds 31 18/58 
Days from diagnosis to first clinic 
(TERTILES) 
≤144 19 9/48 
0.16 125-227 36 16/45 
 ≥228 32 15/47 
Days from end of treatment to first 
clinic (TERTILES) 
≤79 29 14/49 
0.84 80-138 26 12/46 
 ≥139 31 14/45 
Duration of consultation (minutes) 
TERTILES 
≤8 mins 11 4/37  
9-12 mins 29 14/49 0.005 
 ≥13 mins 42 21/50  
Gender Female 37 18/49 
0.12 
 Male 24 22/91 
Age  <55 38 11/29  
 55-64 26 16/52 0.48 
 65-74 31 10/32  
 ≥75 18 3/17  
Tumour site: Oral cavity 18 10/55 
0.10 
 Oropharynx 36 15/42 
 Larynx 30 9/30 
 Other 46 6/13 
Overall clinical stage Advanced 3-4 36 30/84 
0.02 
 Early 1-2 18 10/56 
Primary treatment*: S only 13 6/46 
0.004 
 S only & FF - 0/7 
RT or RT/CT only 39 15/38 
S & (RT or RT/CT) 45 14/31 
S & (RT or RT/CT) & FF 28 5/18 
WHO comorbidity  0 32 28/88 
0.55  1 25 7/28 
 2-4 21 5/24 
ACE27 comorbidity None 32 23/71 
0.25 
 Mild 24 10/41 
 Moderate 20 5/25 
 Severe 67 2/3 
Living situation Alone in house/flat 17  5/29 
0.17 
 With others in house/flat 32 35/111 
Working Yes 29 14/48 
>0.99 
 No 29 25/86 
Financial benefits Yes 31 15/49 
0.69 
 No 27 21/78 
Smoking habit Current 19 3/16 
0.48  Former 27 22/81 
 Never 34 13/38 
Alcohol habit Current 24 24/100 
0.10  Former 37 11/30 
 Never 60 3/5 
IMD 2019 quintile 1=least deprived 50 8/16 
0.32 
 2 28 8/29 
 3 18 4/22 
 4 24 4/17 
 5=most deprived 29 16/56 
* Surgery (S), RadioTherapy (RT), ChemoTherapy (CT), Free Flap transfer (FF) 






Table 2: Selection of the PCI ‘fatigue’ item, by QOL measures  
     




  % Patients  
 All patients 29 40/140  
UWQOL Overall Quality of 
life 
Outstanding/ Very good 11 5/47 
0.002 
Good 31 15/48 
 Fair 41 14/34 
 Very Poor / Poor  55 6/11 
Distress thermometer (DT) Zero 11 4/36 
0.02 
 1-3 26 10/38 
 4-5 39 13/33 
 6-10 39 13/33 
UWQOL social-emotional 
subscale 
<60 52 13/25  
60-79 40 21/53 <0.001 
80-100 10 6/62  
UWQOL physical function 
subscale 
<60 39 16/41  
60-79 36 20/55 0.001 
 80-100 9 4/44  






Social-emotional subscale     
 Pain Best possible response  17 9/53 
0.05  Somewhere in-between 33 16/48 
 Dysfunction 38 15/39 
 Activity Best possible response  7 3/46 
<0.001  Somewhere in-between 36 29/80 
 Dysfunction 57 8/14 
 Recreation Best possible response  11 7/61 
<0.001  Somewhere in-between 39 28/71 
 Dysfunction 63 5/8 
 Shoulder Best possible response  26 22/85 
0.64  Somewhere in-between 34 14/41 
 Dysfunction 29 4/14 
 Mood Best possible response  8 4/48 
<0.001  Somewhere in-between 41 31/75 
 Dysfunction 29 5/17 
 Anxiety Best possible response  15 7/47 
0.003  Somewhere in-between 29 20/69 
 Dysfunction 54 13/24 
Physical function subscale     
 Appearance Best possible response  21 9/43 
0.41  Somewhere in-between 31 27/86 
 Dysfunction 36 4/11 
 Swallowing Best possible response  14 7/50 
0.01  Somewhere in-between 36 26/73 
 Dysfunction 41 7/17 
 Chewing Best possible response  19 11/57 
0.11  Somewhere in-between 36 23/64 
 Dysfunction 32 6/19 
 Speech Best possible response  28 18/64 
0.68  Somewhere in-between 27 18/66 
 Dysfunction 40 4/10 
 Taste Best possible response  12 5/41 
0.008  Somewhere in-between 32 23/72 
 Dysfunction 44 12/27 
 Saliva Best possible response  12 5/41 
0.001  Somewhere in-between 23 11/47 
 Dysfunction 46 24/52 
Other items:     
 Intimacy Best possible response  25 27/110 
0.04  Somewhere in-between 50 12/24 
 Dysfunction 17 1/6 
 16 
 Fear of 
recurrence* 
0 or 25 50 8/16 
0.01 
50 40 17/43 
 75 21 13/62 
 100 11 2/19 
EQ-5D     
Mobility (walking about) No problems 25 24/96 
0.36  Slight problems 37 7/19 
 Moderate/severe/unable 36 9/25 
Self-care (washing or 
dressing myself) 
No problems 24 27/113 
0.03 Slight problems 55 6/11 
 Moderate/severe/unable 44 7/16 
Usual activities No problems 16 12/76 
<0.001  Slight problems 31 11/35 
 Moderate/severe/unable 59 17/29 
Pain (or discomfort) No pain or discomfort 15 8/54 
0.01  Slight pain or discomfort 33 14/42 
 Moderate/severe/extreme 41 18/44 
Anxiety/depression Not anxious or depressed 21 14/67 
0.01  Slightly anxious or depressed 29 17/58 
 Moderate/severe/extreme 60 9/15 
EQ-5D-5L TTO crosswalk 
values (TERTILES) 
≤.6950 45 17/38  
.6951-.8370 31 19/61 0.001 
 ≥.8371 10 4/41  
EQ5D Visual analogue scale 
(VAS) TERTILES 
≤69 46 21/46  
70-81 32 14/44 <0.001 
 ≥82 10 5/50  
 
*(0) I am fearful all the time that my cancer might return and I struggle with this n=2,  (25) I get a lot of fears of recurrence and these can 
really preoccupy my thoughts  n=14,  (50) I am sometimes having fearful thoughts but I can usually manage these (75) I have a little fear 
with occasional thoughts but they don’t really bother me (100) I have no fear of recurrence 
** Fishers Exact test   
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Table 3:  Selection of the PCI ‘fatigue’ item and other PCI data  




  % Patients  
 Patients 29 40/140  
No of PCI selected: overall <5 2 1/57  
 5-9 30 15/50 <0.001 
 10-14 65 13/20  
 ≥15 85 11/13  
PCI items selected by domain:    
Physical function <5 8 6/75  
 5-9 37 16/43 <0.001 
 ≥10 82 18/22  
Cancer treatment   None 24 24/98 
0.11 
 ≥1 38 16/42 
Social care & social 
wellbeing 
None 23 25/109 
0.01 
≥1 48 15/31 
Psychological, emotional 
wellbeing/spiritual 
None 11 7/65  
1 27 12/44 <0.001 
 ≥2 68 21/31  
No. of Health 
professionals selected  
None 23 17/75 
0.05 
≥1 35 23/65 
Other PCI items selected 
by at least 20% of patients 
overall 
Dry mouth 40 27/68 0.005 
Fear of cancer coming back 48 23/48 <0.001 
Dental health/Teeth 44 21/48 0.006 
 Chewing/eating 43 20/46 0.009 
 Salivation 48 22/46 0.001 
 Swallowing 51 20/39 <0.001 
 Taste 42 16/38 0.04 
 Sore mouth  45 15/33 0.03 
 Mucus 48 16/33 0.007 
 Shoulder 45 14/31 0.03 
 Pain in the head and neck 57 17/30 <0.001 
 Cancer treatment 39 11/28 0.17 
Other PCI items* Activity 50 3/6 0.35 
 Appetite 52 14/27 0.004 
 Bowel habit 50 6/12 0.10 
 Breathing 67 6/9 0.02 
 Energy levels 60 15/25 <0.001 
 Indigestion 50 3/6 0.35 
 Mobility 70 7/10 0.006 
 Nausea 83 5/6 0.007 
 Pain elsewhere 54 7/13 0.05 
 Sleeping 81 13/16 <0.001 
 Vomiting 80 4/5 0.02 
 Financial benefits 67 4/6 0.06 
 Speech/voice/being 
understood 
60 9/15 0.01 
 Anxiety 56 9/16 0.02 
 Depression 75 6/8 0.007 
 Memory 60 6/10 0.03 
 Mood 83 5/6 0.007 
 Self-esteem 67 4/6 0.06 
 Personality & temperament 60 3/5 0.14 
Other Health professionals*    
 Oral rehab team 57 4/7 0.10 
 Physiotherapy 63 5/8 0.04 
 Audiologist 50 4/8 0.23 
 
*when these items were selected then Fatigue was selected in at least 50% of the patients. Denominators under 5 were omitted 
 
